OCA2 and glioblastoma: In a study with high-grade glioma patients (n = 141), of which 68.1% with glioblastoma, three potential biomarkers were identified: low platelet count, elevated D-dimer, and high soluble P (sP)-selectin.125In addition, FVIII activity and leukocyte count both showed borderline significance.